Search

Vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC) are two groups of drugs used in the prevention of thromboembolic events. Although DOACs are currently the preferred option in such prophylaxis, there are still indications for the use of VKAs. Thromboembolic episodes may occur as a result of many cardiovascular diseases, inter alia cardiac dysrhythmias. Atrial fibrillation is an arrhythmia that may be asymptomatic or manifested by chest pain, syncope, dyspnea or fatigue. Moreover, it is associated with a high risk of serious complications. An ischemic stroke or myocardial infarction can result from poorly treated AF and may sometimes be the only symptom of an arrhythmia. Therefore, the assessment of a patient's eligibility for anticoagulation therapy is an important element in the prevention of thromboembolic events. Demographic aging and the associated comorbidity may pose a clinical problem in the treatment of atrial fibrillation. The selection of an appropriate anticoagulant therapy should be individualized to the patient's needs.

Purpose of the study: to assess the role of educational programs on anticoagulant therapy in patients with atrial fibrillation in increasing adherence to warfarin treatment.Material and methods: the study included patients with atrial fibrillation, divided into two groups: the main group (n=125) - patients who completed the training program, and the control group (n=216), randomized for routine care, without training sessions. Comparison of the groups were comparable in sex (55.8% of men and 44.2% of women – in main group and 62.4% of men (p

The article presents a clinical analysis of the patient with a newly developed unprovoked episode of venous thromboembolic events. It discusses the challenges in the diagnosis of pulmonary embolism, the need for thrombolytic therapy in patients with pulmonary arterial thromboembolism of medium risk. The guidelines for diagnosis of antiphospholipid syndrome in accordance with modern principles are provided. It also considers the issues of anticoagulant treatment.

The article presents a clinical discussion of the patient with recurrent venous thromboembolic complications. It also provides recommendations on modern principles of diagnostics, choice of medical tactics in patients with this pathology. Much attention is paid to the issues of anticoagulant treatment, which inadequacy or failure results in the development of severe, difficultly treatable complications.

The review tells about challenges of antithrombotic therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivaroxaban, low doses of which are officially indicated for the prevention of cardiovascular death and myocardial infarction in patients after acute coronary syndrome occurring with increased values of myocardial injury markers. Clinical characteristics of patients feasible for this treatment approach are considered.

The article takes into consideration practical issues of novel oral anticoagulants (factor Xa inhibitors) usage with the aim of prevention of thromboembolic complications in nonvalvular atrial fibrillation.A clinical case presented the patient with this pathology under high risk of thromboembolic complications with several years follow-up.

Kovbasniuk Yuriy, Plenova Olga. Anticoagulant treatment of af: focus on the warfarin dosage. Journal of Education, Health and Sport. 2015;5(10):323-326. ISSN 2391-8306. DOIhttp://dx.doi.org/10.5281/zenodo.35295 http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%2810%29%3A323-326 https://pbn.nauka.gov.pl/works/679056 Formerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011–2014http://journal.rsw.edu.pl/index.php/JHS/issue/archive Deklaracja. Specyfika i zawartość merytoryczna czasopisma nie ulega zmianie. Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., że w roku 2014 nie będzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktów co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r. The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014). © The Author (s) 2015; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 25.09.2015. Revised 25.10.2015. Accepted: 31.10.2015. Anticoagulant treatment of AF: Focus on the warfarin dosage Yuriy Kovbasniuk, Olga Plenova National Medical University, Kyiv, Ukraine Summary Authors analyzed the results of some studies of AF and warfarin dosing. Than investigation of 75 patient with AF (permanent type) was performed. According to demographic, anthropometric data and related conditions (diabetes mellitus type 2, myocardial infarction, acute cerebrovascular ischemia, pulmonary embolism, alcohol abuse - drinking more than one ounce of ≥3 weekly) predictive model of warfarin dosing was developed: warfarin dose = 0.097 * BMI - 0.03 * AGE + 0.30 *ASS.Status+ 0.02 *WC+ 1, 88. After testing of final model authors concluded what derived formula was representative, to determine the optimal dose of warfarin given to patient based on demographic characteristics. Considering all of the abovementioned, this model can be recommended for use determining the treatment strategy in patients with AF. Keywords: anticoagulant treatment, warfarin, atrial fibrillation.